Erectile dysfunction drugs

PDE5 inhibitors (oral)
Other names	Sildenafil (Viagra), tadalafil (Cialis), avanafil (Stendra), vardenafil (Levitra)
Health risk	Mild to Moderate (hypotension, priapism, NAION; dangerous interactions with poppers)
Addiction risk	Low
Legal risk	Mild (prescription required in most jurisdictions)
External links	Drugs.com · Mayo Clinic

This page covers oral medications. For the injectable treatment, see Trimix.

Oral PDE5 inhibitors are a class of prescription medications that treat erectile dysfunction (ED) by enhancing the effect of nitric oxide (NO) on penile smooth muscle. The four most common agents are sildenafil (Viagra), tadalafil (Cialis), avanafil (Stendra), and vardenafil (Levitra). They are competitive inhibitors of phosphodiesterase type 5, an enzyme that degrades cyclic guanosine monophosphate (cGMP). By maintaining higher cGMP levels, these drugs prolong vasodilation and facilitate firm, sustained erections – but only in the presence of sexual stimulation. They do not increase libido.

Within Risk-Aware Consensual Kink (RACK), PDE5 inhibitors are often used to extend scenes, manage performance anxiety, or counteract stimulant-induced ED. However, their use, especially when combined with other chemsex substances, demands thorough risk awareness and explicit, ongoing consent from all participants.

Background and mechanism of action

PDE5 inhibitors work by competitively binding to the catalytic site of PDE5, preventing the enzyme from hydrolyzing cGMP to 5′-GMP. cGMP is produced in response to nitric oxide release from nerve endings and endothelial cells during sexual arousal; it relaxes smooth muscle in the corpora cavernosa, allowing blood to fill the sinusoids and create an erection. Systemic PDE5 inhibition also affects vascular smooth muscle elsewhere, notably in the pulmonary arteries and systemic arterioles, causing a modest decrease in blood pressure (5–10 mmHg systolic).

Sildenafil and vardenafil are structurally similar and have comparable selectivity for PDE5, while tadalafil has a longer half‑life due to slower hepatic clearance. Avanafil boasts a faster onset, which may reduce the planning window.

Medical uses (non-kink)

• Erectile dysfunction (first-line)
• Pulmonary arterial hypertension (sildenafil 20 mg three times daily as Revatio; tadalafil 40 mg once daily as Adcirca)
• Benign prostatic hyperplasia (tadalafil 5 mg once daily)
• Raynaud’s phenomenon (off-label)

All are available by prescription only.

Contraindications

Absolute contraindications:

• Concomitant use of organic nitrates (nitroglycerin, isosorbide mononitrate/dinitrate) — profound hypotension.
• Use of nitric oxide donors (e.g., molsidomine, nicorandil).
• Known hypersensitivity to any component.
• Severe hepatic impairment.
• Patients for whom sexual activity is inadvisable due to cardiovascular risk (unstable angina, recent myocardial infarction, severe aortic stenosis).

Relative contraindications include anatomical penile deformities (Peyronie’s disease), conditions predisposing to priapism (sickle cell anemia, leukemia), and active peptic ulcer disease.

Appeal in kink and chemsex

In BDSM and chemsex contexts, these medications are used to:

• Enable longer or multiple penetrative sessions
• Counteract ED caused by stimulants (cocaine, methamphetamine)
• Increase physical confidence and reduce anxiety-related ED
• Support scenes emphasizing sexual endurance or power exchange

The most dangerous aspect is the frequent combination with poppers (alkyl nitrites). This interaction is addressed in detail below.

Onset and duration

Comparative pharmacokinetics of oral PDE5 inhibitors

Drug	Brand	Onset (fasted)	Tmax (fed)	Duration (effective)	Notes
Sildenafil	Viagra, Kamagra	30–60 min	delayed 1–2 h with fat	4–5 h	Food slows absorption; avoid grapefruit juice.
Tadalafil	Cialis, Cialis Daily	30–45 min	minimal delay	24–36 h	Daily 5 mg provides steady state; not affected by food.
Avanafil	Stendra, Spedra	15–30 min	delayed with high fat	6–12 h	Fastest onset; can be taken close to activity.
Vardenafil	Levitra, Staxyn	30–60 min	delayed with fat	4–5 h	Orally disintegrating tablet available.

Risks

Hypotension

All PDE5 inhibitors cause vasodilation, which lowers systemic blood pressure. In healthy adults, the decrease is typically 5–10 mmHg systolic and rarely symptomatic. However, when combined with other vasodilators — especially poppers (alkyl nitrites) — the drop can exceed 30 mmHg and lead to syncope, myocardial ischemia, or cardiac arrest. Symptoms of significant hypotension include dizziness, blurred vision, confusion, fatigue, and fainting. If these occur, the subject must lie supine with legs elevated; if consciousness is lost, call emergency services immediately.

Priapism

Priapism is a persistent, often painful erection lasting >4 hours, unrelated to sexual stimulation. It results from failure of venous outflow, leading to cavernosal ischemia. Without prompt treatment, endothelial damage and fibrosis can cause permanent erectile dysfunction. Immediate medical attention is required; aspiration with phenylephrine injection is the standard therapy. Risk factors: sickle cell disease, multiple myeloma, trazodone use, and intracavernosal injections.

Visual and auditory adverse effects

• Non-arteritic anterior ischemic optic neuropathy (NAION): Sudden unilateral vision loss due to infarction of the optic nerve head. Associated with PDE5 inhibitors, particularly in patients with crowded optic discs, hypertension, diabetes, and hyperlipidemia. Any acute vision change warrants immediate ophthalmologic evaluation.
• Sudden sensorineural hearing loss: Rare, reported post‑marketing. May be accompanied by tinnitus and dizziness.

Other common side effects

• Headache (10–16%)
• Flushing (7–10%)
• Dyspepsia (4–7%)
• Nasal congestion (2–4%)
• Back pain/myalgia (particularly tadalafil, ~3%)

These are usually transient and dose‑dependent.

Drug interactions

Poppers (alkyl nitrites)

The most critical and potentially fatal interaction is with alkyl nitrites. Poppers act as nitric oxide donors, which synergistically increase cGMP production while PDE5 inhibitors block its degradation. The combined profound vasodilation can reduce diastolic blood pressure to critical levels, leading to coronary hypoperfusion, myocardial infarction, and death. Multiple case reports document fatalities. There is no safe way to combine them; even a single inhalation can trigger a crisis.

Antihypertensives

Additive effect with alpha‑blockers, beta‑blockers, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers. Doses should be titrated carefully, and PDE5 inhibitors are best taken at the lowest effective dose.

Stimulants

Sympathomimetics like cocaine and methamphetamine increase heart rate and blood pressure, which can mask PDE5‑induced vasodilation or provoke arrhythmias. The combined cardiovascular strain is unpredictable; the NHS explicitly warns against using sildenafil with recreational stimulants.

Alcohol

Moderate alcohol consumption does not significantly alter PDE5 inhibitor effects, but heavy drinking increases the risk of orthostatic hypotension, impairs judgment, and may delay drug absorption.

Consent and safety in chemsex

In a RACK‑based scene, using PDE5 inhibitors demands explicit, informed consent:

• All parties must be aware of which drug has been taken, dose, and time of ingestion.
• The life‑threatening interaction with poppers must be disclosed; no participant should introduce poppers unknowingly.
• Decision to use must be made sober, before any intoxication.
• The Top/Dominant should monitor for signs of hypotension or distress, and the bottom must have a non‑verbal safeword if dizziness prevents speech.
• Nobody should be pressured to take ED medication; refusal must be respected unconditionally.

Risk mitigation

• Obtain a legal prescription: Counterfeit drugs often contain toxic fillers or unlabeled active ingredients (e.g., methamphetamine, fentanyl). A pharmacy‑dispensed product ensures purity and correct dosage.
• Never combine with poppers: This rule is absolute; there is no safe dose window.
• Start low, go slow: Use the smallest effective dose (sildenafil 25–50 mg; tadalafil 5–10 mg; avanafil 50 mg; vardenafil 5–10 mg). Higher doses increase side effects without proportionate benefit.
• Avoid high‑fat meals before short‑acting agents: Fat delays absorption of sildenafil and vardenafil, reducing predictability.
• Hydrate adequately: Dehydration exacerbates hypotension.
• Know priapism first‑aid: If erection persists >2–3 hours, go to the emergency department. Do not wait or attempt to mask symptoms.

Known incidents

Deaths related to PDE5 inhibitor + popper combination

McCabe et al. (2012) reported severe methaemoglobinemia and cardiovascular collapse following combined sildenafil and popper use. Additional fatal cases are referenced in the Poppers article.

RACKWiki incident reports

Community‑submitted reports are collected at RACKWiki:Incident_reports/PDE5_inhibitors. Editors are encouraged to share anonymised, verified experiences.

External links

• PDE5 inhibitors on Drugs.com
• Oral ED medications on Mayo Clinic
• Sildenafil (Viagra) on NHS